Página 7 - Melhores Biópsia mamária médicos - TOP-144 médicos

Dr. Jelena is a Specialist Obstetrician & Gynecologist with over 25 years of experience in her field. She began her medical studies in 1986 at the University of Belgrade Medical School, Belgrade. She completed her primary Medical Degree in 1992 and continued with her internship the following year at the Clinical Centre of Serbia while working as a General Practitioner.

Dr. Jelena has worked at the Gynecology & Obstetrics Clinic Narodni front (Belgrade, Serbia), Special Gynecology Hospital Genesis Medical (Belgrade, Serbia) and General Hospital ST MEDICA (Belgrade, Serbia).

She also worked for two years as a Professor in Gynaecology & Obstetrics for students of the High Medical School, Belgrade, Serbia. She held a post as a Consultant in Gynaecology & Obstetrics for several private clinics in Belgrade.
In April 2016, she moved to Dubai where she started to work as Gynaecology & Obstetrics Specialist.

She specialises in Gynaecological and Obstetrical Ultrasound (4D ultrasound), Gynaecology Endocrinology, Lower Genital Tract Pathology, Hysteroscopy, Prenatal and Post-natal care, Antiaging Treatment, Laser Treatment for Stress Urinary Inconsistency and Vaginal Relaxation Syndrome, Laser Vaginal Tightening, Laser Vaginal Rejuvenation/Vaginal Atrophy Laser Treatment, Invasive and Non-Invasive Gynaecological Diagnosis (HSSG, SIS, HSG) & Aesthetic Gynaecology.

Medical Field of lnterest

Invitrofertilization , Repeated ivf failure, Recurrent miscarriage, Reproductive immunology, Labioplasty ,Vaginoplasty

Memberships

• Turkish Medical Association

• Turkish Society of Gynecology and Obstetrics(TJOD)

• Society for IVF and Infertility (TUBID)

• European Society for Human Reproduction and Embryology (ESHRE)

Courses and Training Programs Attended

1. Experimental Animal Use and Ethical Approach - Marmara University Faculty of Medicine 2003

2. Early Pregnancy Ultrasound Course - Istanbul 2004

3. Neonatal Resuscitation Program -Istanbul 2004

4. Basic Statistics Training Course - Marmara University Faculty of Medicine 2004

5. 3D Vienna International School of 3D Ultrasonography - Vienna 2005

6. 8th Turkish-German Gynecology Congress- Colposcopy Course -Antalya 2009

7. Colposcopy Course- TJOD Istanbul Branch 2009

8. Health Law Certificate Program - Istanbul 2010

9. Expert Witness Training Program in Cases Arising from Medical Interventions - Istanbul 2014

10. Ovulation Induction Course- 4th Acibadem Days- Istanbul 2016

11. Emergency Obstetric Care Clinician Training - Ministry of Health - 2019

12. Aesthetic Genital Surgery Fellowship - The British Academy of CME- 2023

13. International Cosmetic and Functional Gynecology- ISAGSS- 2023

Dr. Fernandez Oliva graduated with honors from the Faculty of Medicine of the Universitat Autònoma de Barcelona, specializing in Medicine and Surgery.

Completed his residency in Obstetrics and Gynecology at the Hospital de la Vall d'Hebrón, Barcelona.

The doctor combines clinical practice with continuous education and scientific work.

Lecturer at the CTO Medical Academy.

Participant of courses and congresses:

- Congress of the European Society for Gynaecological Endoscopy (ESGE), 2015

- Course in Medical Genetics and Fetal Medicine, Catalan Society of Obstetrics and Gynecology, Barcelona 2015

- Course in robotic and laparoscopic surgery, Hospital Vall d'Hebrón, Barcelona 2016

- Congress of the Sociedad Española de Ginecología y Obstetricia (SEGO), 2017.

Current areas of scientific research:

- Prevention of preeclampsia in early pregnancy

- Immunological interaction between the mother and the fetus

An expert in the comprehensive care of women, she specialised in medical care projects focusing on the Humanised Childbirth Program and the development and promotion of low-intervention obstetric care.

She is currently the Head of the Obstetrics and Gynaecology Unit of the Quirónsalud Marbella Hospital. She has promoted the implementation of a specific protocol for Humanised C-section in this hospital to ensure the active participation of women in the arrival of their babies and a childbirth plan that is similar to natural childbirth.

Dr Blanco Herráez has also promoted the implementation of the current Multidisciplinary Breast Unit, the objective of which is the management of breast cancer, both from the preventative and the early detection points of view, as well as the diagnosis, treatment, follow-up and functional and psychological recovery of patients.

Training

- Son Espases Mallorca Hospital, Palma de Mallorca | 05/2007 - 05/2011 Resident Doctor in the Gynaecology speciality.

- Madrid Complutense University, Madrid 09/2000 - 06/2006. Medicine

Working Experience

- Quirónsalud Marbella Hospital- Head of the Gynaecology and Obstetrics Unit | 04/2022 – Currently

- Fundación Jimenez Díaz University Hospital- Obstetrics and Gynaecology Consultant | 06/2011 - 04/2022

- Fundación Jimenez Díaz University Hospital -Teaching Obstetrics and Gynaecology Residents 06/2012- 06/2014.

- Fundación Jimenez Díaz University Hospital - Cooperating Teacher 06/2016- 06/2022

Memberships

- Member of the Madrid Professional Medical Association since June 2011.

- Member of the Spanish Society of Obstetrics and Gynaecology since October 2008.

- Member of the Spanish Society of Cervical Pathology and Colposcopy since 2011.

The primary objective of the Obstetrics and Gynaecology Unit of the Quirónsalud Marbella Hospital is to provide a high-quality comprehensive care service to women and their health issues at any of their life stages. Specially, issues deriving from pregnancy, childbirth and the post childbirth stage, as well as any matters relating to the female organs and reproductive functions.

A highly-qualified multidisciplinary team that positions each patient at the core in order to ensure the provision of a professional and personalised service adapted to the health needs and expectations of women. Besides, an early diagnosis and treatment customised to each personal circumstance, the promotion of health and the prevention of disease are at the core of the work of the Obstetrics and Gynaecology Unit.

Efficiency, innovation, the use of new technologies and digitalisation are differential factors of the care service provided by the over 30 health professionals (doctors, nurses, assistant nurses and midwives) who make up the team of this speciality.

Dr. Namrata Jadhav brings with her more than 14 years of experience in the field of Obstetrics and Gynaecology. She has pursued MBBS, DNB, GO, MNAMS from leading colleges and hospitals in Mumbai, India. She has obtained training in Cosmetic Gynaecology in UAE. She has also taken laparoscopic training in a year 2016 and 2022.
Dr. Namrata is proficient in High-Risk Obstetrics, hypertension/diabetes in pregnancy, recurrent abortions, previous LSCS, vaginal birth after LSCS, management of pregnancy after IV/infertility treatment, just to name a few.

She also has a passion for pre-pregnancy, pregnancy counselling to make the journey a memorable, postpartum care and weight management, and is even known for painless pap smears and examinations. Dr. Namrata is also proficient in treating recurrent UTI/vaginal infections, handling cosmetic gynaecology cases, and is an expert when it comes to POS management, PCO related issues, and abnormal bleeding in adolescence.

Dr Seree Teerapong, M.D.

OBSTETRICIAN AND GYNECOLOGIST (IN–VITRO FERTILIZATION: IVF)

Graduation (M.D. From)

Bachelor of Medicine, Faculty of Medicine, Chiang Mai University

Certificates

1. Diploma in Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University
2.  
3. Diploma in Reproductive Medicine, Medical Council of Thailand
4. Certificate in Laparoscopic Gynecological Surgery, Medical Council of Thailand

Current Positions

Obstetrician and gynecologist (IN-VITRO FERTILIZATION: IVF) at Intrarat Hospital

A Dra. Séverine Iborra é a Médica Chefe do Departamento de Ginecologia e Obstetrícia do Städtisches Klinikum Solingen. Suas responsabilidades incluem obstetrícia, a sala de parto, a unidade neonatal e ginecologia. O departamento também inclui a Clínica de Senologia/Mama no Centro de Mama Bergisches Solingen, liderada pela Dra. Manuela Seifert.

A Dra. Séverine Iborra é originária da França. Ela iniciou seus estudos de medicina na Universidade de Lyon e, posteriormente, transferiu-se para a Universidade Albert-Ludwigs em Freiburg, onde obteve sua licença médica em 2007. Ela obteve seu doutorado em 2008 por meio de pesquisa experimental em oncologia molecular. De agosto de 2008 a novembro de 2013, a Dra. Iborra trabalhou como residente na Clínica Universitária de Mulheres em Freiburg. Após passar nos exames de especialista em ginecologia e obstetrícia, continuou sua carreira como especialista na mesma clínica. Em novembro de 2015, ela transferiu-se para o Hospital Universitário RWTH Aachen como médica sênior.

Na Clínica de Ginecologia e Obstetrícia, sob a liderança do Prof. Dr. E. Stickeler, a Dra. Iborra liderou o departamento de obstetrícia de 2017 a 2019. Desde dezembro de 2017, foi responsável pela organização do ensino no departamento, e em outubro de 2019, tornou-se Médica Sênior Gerente e Médica Sênior de Pessoal da clínica, posição que ocupou até se mudar para Solingen.

Além de seu trabalho científico, com inúmeras publicações e apresentações em grandes conferências ginecológicas, a Dra. Iborra aprofundou suas especialidades médicas. Ela obteve certificações em diagnóstico e terapia oncológica do Grupo de Trabalho de Oncologia Ginecológica, bem como qualificações adicionais em Patologia Cervical e Colposcopia (AGCPC), Uroginecologia e Cirurgia Reconstrutiva Pélvica (AGUP), e da Associação Profissional de Ginecologistas (BVF).

Em 2019, a Dra. Iborra concluiu com sucesso uma especialização adicional em “Oncologia Ginecológica” e “Obstetrícia Especial e Medicina Perinatal.” Ela é membro ativo de importantes sociedades médicas alemãs em sua área, incluindo a Sociedade Alemã de Ginecologia e Obstetrícia, o Grupo de Trabalho de Patologia Cervical e Colposcopia, e a Sociedade Alemã de Medicina Pré-Natal e do Parto.

Tratamentos Oferecidos em Nosso Departamento de Ginecologia

• Histeroscopia e Dilatação e Curetagem (D&C) para fins diagnósticos e terapêuticos.
• Remoção de achados ovarianos anormais ou sintomáticos, como cistos, preservando o restante do ovário.
• Ooforectomia (remoção de ovários) em casos de anomalias ou preventivamente quando indicado.
• Miomectomia (remoção de miomas uterinos) preservando o útero.
• Tratamento conservador de miomas: seja medicamentoso ou embolização realizada por especialistas em radiologia.
• Histerectomia com ou sem remoção do colo do útero.
• Diagnóstico e esclarecimento de achados incertos no colo do útero, vagina e vulva.
• Tratamento de displasia.
• Tratamento da endometriose.
• Tratamento do câncer para câncer de vulva, vagina, colo do útero, útero e ovário.
• Tratamento para incontinência e/ou prolapso dos órgãos pélvicos.

Sempre que possível, oferecemos todos os procedimentos como tratamentos minimamente invasivos usando laparoscopia ou o sistema robótico Da Vinci.

 Posts and Affiliations

Clinical Director – Multidisciplinary Breast Unit Kliniken Essen-Mitte, Germany

Lead Breast Cancer Research Program, Kliniken Essen-Mitte

Executive Board Member of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)

 Additional Roles

ESMO Faculty – Breast Cancer

Member of AWO Gyn – Commission for plastic and reconstructive surgery

Speaker of the AGIMed – Commission for Integrative Medicine of the AGO

Member of the Organ Commission Mamma of the AGO

Scientific Director of the WSG study group

Global PI, Head of clinical investigations and trials 27

IDMC´s, Steering Boards national and international

Scientific committee of international and national symposia in breast cancer and surgical oncology

 Organization Memberships

Memberships: European Society of Medical Oncology, American Society of Clinical Oncology,

European Academy of Senology, German Cancer Society, German Society of Gynecology and

Obstetrics, Working Group for Gynecological Oncology, German Society of Senology,

 Publications

Peer reviewed Publications: 322

First/Senior Author: 38

h-Index/i10-Index 66/232

Congress Abstracts/Proceedings: 443

Books/Book Chapter: 59

Invited oral Presentations/Lectures: 1032

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

Education & Expertise

• 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
• 2005 to 2009 – Düzce University, Internal Medicine Specialization
• 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
• 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
• 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
• 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
• 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
• 2020 to Present – Professor, Sakarya University Faculty of Medicine
• 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

• 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
• 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

• TTOD (Turkish Society of Medical Oncology)
• ASCO (American Society of Clinical Oncology)
• ESMO (European Society for Medical Oncology)

Areas of Interests

• Infertility
• In Vitro Fertilization (IVF) Treatment
• Endometriosis
• Urogynecology (urinary incontinence and uterine prolapse surgeries)
• Gynecological Laparoscopic surgeries
• Hysteroscopic surgeries
• Pregnancy Monitoring
• Myoma surgery
• Ovarian cysts and surgeries
• Gynecological plastic surgeries

Education:

• Ataturk University Faculty of Medicine - Undergraduate
• Abant Izzet Baysal University Faculty of Medicine Gynecology and Obstetrics - Specialization
• Bezmialem Vakif University Faculty of Medicine Istanbul - Assistant Professorship
• Bezmialem Vakif University Faculty of Medicine Istanbul - Associate Professorship
• American Hospital - Assisted Reproductive Specialist Training

Experience:

• Bolu Izzet Baysal State Hospital (Compulsory Service) -Bolu
• Bezmialem Vakif University Faculty of Medicine - Istanbul

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Areas of Interests

• Genital Laser Application ( Vajinal  Rejuvenation , Laser Incontinence Treatment)
• Aesthetic  Genital  Surgery ( Labioplastia, Vaginoplastia, Perineoplastia )
• Vaginismus Treatment.
• Treatment Of Female Sexual Function Disorders.
• Hormonal & Non-Hormonal Treatment.
• Laser Incontinence Treatment.
• Medical Treatment İn Incontinence.

Education

• Hacettepe  University  Faculty of  Medicine, ANKARA.
• SBÜ. ANKARA Dr. Zekai Tahir Burak  Training and  Research  Hospital.

Experience

• SBÜ.ANKARA Dr. Zekai Tahir Burak Training and Research Hospital.
• Antalya Training and  Research  Hospital,
• Jinefem , Private Gynecology Center, ANTALYA
• SM Clinic, Private Gynecology Center, ANTALYA
• Liv Hospital Ulus, İSTANBUL

Research:

• Gestational  Diabetic  Evaluation of  Affinity in Pregnant  Woman in Turkey.
• The  Effect of Intrauterin Insemination on  Pregnancy  Rates in Infertile Woman in 456 cycles.
• The  Effect of  Genital  Laser  Applications on  Urinary  Incontinence  Treatment.
• The  Effect of  Genital  Laser  Applications  on  Vaginal  Atrofi  in  Menopause.
• Distribution of Human Papilloma Virus (HPV) İnfection in the Mediterranean Region in Turkey.

Doctor Brenda Pastrana is a mexican surgical Oncologist. 

Medical background.

Centro Medico Nacional 20 de Noviembre Issste, Surgical Oncologist in 2020.

Title by Universidad Autónoma de México UNAM.

Surgical Residency Instituto Mexicano del Seguro Social. 2015.

Title by Universidad de Quintana Roo. 

Board Certified by Conacem from 2020 to 2025 number 2171 

Board Certified by Conacem from 2025 to 2030 number 2171

Member of SMEO. Sociedad Mexicana de Oncología. 

University teacher at Universidad Anahuac of Medicine since 2020.

Dr. Gulcan Albayrak is a gynecology and women’s health specialist. She trained at Uludağ University Faculty of Medicine, Ankara Zekai Tahir Burak Women’s Health Training and Research Hospital, and the Harris Birthright Fetal Medicine Research Center in London. She has worked at Medicine Hospital, Private İlke Hospital, Private GOP Hospital, Ankara Çankaya Özel Hasvak Hospital, and Erzincan State Hospital. She also served as a specialist at Medcare Hospital, Dubai.

Her advanced training includes hysteroscopy (Sunrise Hospital, Kerala) and colposcopy (Istanbul University–Çapa). She also trained in non-hormonal menopause care (Exeltis, Madrid), MonaLisa Touch CO2 vaginal laser, genital aesthetics (ICC), and vulvar filler/PRP. She holds a Ministry of Health–approved mesotherapy certificate. She is a member of TJOD, TSRM, the Turkish-German Gynecology Association, EJD, ITO, and ESAG. Publications include “Reproductive outcome of septate uterus after hysteroscopic metroplasty” (Archives of Gynecology & Obstetrics, Vol. 26B, Issue 4, Oct 2003, ZaS-ZSZI) and a cervical rhabdomyosarcoma case report (poster, Antalya Congress).